DelveInsight Highlights Major Advances, Transformative Therapies, and 50+ Leading Players Wheeling the Advanced Ovarian Cancer Clinical Trial Pipeline Landscape
The Advanced Ovarian Cancer Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Advanced Ovarian Cancer treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Advanced Ovarian Cancer pipeline landscape and fostering the potential growth of Advanced Ovarian Cancer therapeutic advancements.
Key Takeaways from the Advanced Ovarian Cancer Pipeline Report
- DelveInsight’s Advanced Ovarian Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Ovarian Cancer treatment.
- The leading companies working in the Advanced Ovarian Cancer market include OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo Inc., Astellas Pharma Inc., and others.
- Promising Advanced Ovarian Cancer Pipeline Therapies in the various stages of development include 2X-121, Bevacizumab, Durvalumab, Olaparib, Neoadjuvant Chemotherapy, Carboplatin, MM-121, Paclitaxel, Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), AGS-8M4, Trabectedin, Dexamethasone, IMAB027, Niraparib, EP0057, Defactinib, and others.
- On January 2023, Grupo Español de Investigación en Cáncer de Ovario announced a study of Phase 2 Clinical Trials for Olaparib and Pegylated Liposomal Doxorubicin. Impact of the combination of Olaparib and Pegylated Liposomal Doxorubicin on improvement of progression-free survival at 6 months in patients with platinum resistant advanced ovarian cancer.
- On February 2023, Tesaro Inc. announced a study of Phase 3 Clinical Trials for Niraparib. This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer. Participants must have completed front-line platinum based regimen with complete response (CR) or partial response (PR). Data collection for Secondary Outcome measures is ongoing and the approximate duration of the study will be 7 years.
- On March 2023, Allarity Therapeutics announced a study of Phase 2 Clinical Trials for 2X-121. This study is to be performed as an open label, multicenter, single arm study of 2X-121 to evaluate anti-tumor efficacy of 2X-121 as single agent therapy in a 28-days cycle in advanced ovarian cancer patients. 2X-121 will be supplied for oral administration once daily as 600 mg (3 x 200 mg) capsules in a 28 days cycle.
- On August 2023, AstraZeneca announced a study of Phase 3 Clinical Trials for Bevacizumab, Durvalumab, and Olaparib. This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
Request a sample and discover the recent advances in Advanced Ovarian Cancer Treatment Drugs @ Advanced Ovarian Cancer Infection Pipeline Report
The Advanced Ovarian Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Ovarian Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Ovarian Cancer clinical trial landscape.
Advanced Ovarian Cancer Overview
Advanced Ovarian Cancer means that the cancer has spread outside the ovary. It may have spread within the pelvis or abdomen, or further away to other parts of the body such as the lungs. Some women have Advanced Ovarian Cancer when they are first diagnosed, and treatment can cure their cancer.
Find out more about Advanced Ovarian Cancer Treatment Drugs @ Drugs for Advanced Ovarian Cancer Treatment
Advanced Ovarian Cancer Emerging Drugs Profile
- Oregovomab: OncoQuest
- Stenoparib: Allarity Therapeutics
- DP-303c: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Ovarian Cancer Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for advanced ovarian cancer. The Advanced Ovarian Cancer companies which have their advanced ovarian cancer drug candidates in the most advanced stage, i.e. phase III include, OncoQuest.
Learn more about the emerging Advanced Ovarian Cancer Pipeline Therapies @ Advanced Ovarian Cancer Clinical Trials Assessment
Scope of the Advanced Ovarian Cancer Pipeline Report
- Coverage- Global
- Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Advanced Ovarian Cancer Companies- OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo Inc., Astellas Pharma Inc., and others.
- Advanced Ovarian Cancer Pipeline Therapies- 2X-121, Bevacizumab, Durvalumab, Olaparib, Neoadjuvant Chemotherapy, Carboplatin, MM-121, Paclitaxel, Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), AGS-8M4, Trabectedin, Dexamethasone, IMAB027, Niraparib, EP0057, Defactinib, and others.
Dive deep into rich insights for new drugs for Advanced Ovarian Cancer Treatment, Visit @ Advanced Ovarian Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Advanced ovarian cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Advanced ovarian cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Advanced ovarian cancer Collaboration Deals
- Late Stage Products (Phase III)
- Oregovomab: OncoQuest
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Stenoparib – Allarity Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- DS-6000a: Daiichi Sankyo Company
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Advanced ovarian cancer Key Companies
- Advanced ovarian cancer Key Products
- Advanced ovarian cancer- Unmet Needs
- Advanced ovarian cancer- Market Drivers and Barriers
- Advanced ovarian cancer- Future Perspectives and Conclusion
- Advanced ovarian cancer Analyst Views
- Advanced ovarian cancer Key Companies
- Appendix
For further information on the Advanced Ovarian Cancer pipeline therapeutics, reach out to Advanced Ovarian Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting
